Breast-cancer risk in families with mutations in PALB2
- PMID: 25099575
- PMCID: PMC4157599
- DOI: 10.1056/NEJMoa1400382
Breast-cancer risk in families with mutations in PALB2
Abstract
Background: Germline loss-of-function mutations in PALB2 are known to confer a predisposition to breast cancer. However, the lifetime risk of breast cancer that is conferred by such mutations remains unknown.
Methods: We analyzed the risk of breast cancer among 362 members of 154 families who had deleterious truncating, splice, or deletion mutations in PALB2. The age-specific breast-cancer risk for mutation carriers was estimated with the use of a modified segregation-analysis approach that allowed for the effects of PALB2 genotype and residual familial aggregation.
Results: The risk of breast cancer for female PALB2 mutation carriers, as compared with the general population, was eight to nine times as high among those younger than 40 years of age, six to eight times as high among those 40 to 60 years of age, and five times as high among those older than 60 years of age. The estimated cumulative risk of breast cancer among female mutation carriers was 14% (95% confidence interval [CI], 9 to 20) by 50 years of age and 35% (95% CI, 26 to 46) by 70 years of age. Breast-cancer risk was also significantly influenced by birth cohort (P<0.001) and by other familial factors (P=0.04). The absolute breast-cancer risk for PALB2 female mutation carriers by 70 years of age ranged from 33% (95% CI, 25 to 44) for those with no family history of breast cancer to 58% (95% CI, 50 to 66) for those with two or more first-degree relatives with breast cancer at 50 years of age.
Conclusions: Loss-of-function mutations in PALB2 are an important cause of hereditary breast cancer, with respect both to the frequency of cancer-predisposing mutations and to the risk associated with them. Our data suggest the breast-cancer risk for PALB2 mutation carriers may overlap with that for BRCA2 mutation carriers. (Funded by the European Research Council and others.).
Conflict of interest statement
No other potential conflict of interest relevant to this article was reported.
Figures
Comment in
-
PALB2 mutations and breast-cancer risk.N Engl J Med. 2014 Aug 7;371(6):566-8. doi: 10.1056/NEJMe1405784. N Engl J Med. 2014. PMID: 25099582 Free PMC article. No abstract available.
-
Breast-cancer risk in families with mutations in PALB2.N Engl J Med. 2014 Oct 23;371(17):1651-2. doi: 10.1056/NEJMc1410673. N Engl J Med. 2014. PMID: 25337756 No abstract available.
-
Breast-cancer risk in families with mutations in PALB2.N Engl J Med. 2014 Oct 23;371(17):1650. doi: 10.1056/NEJMc1410673#SA1. N Engl J Med. 2014. PMID: 25337757 No abstract available.
-
Breast-cancer risk in families with mutations in PALB2.N Engl J Med. 2014 Oct 23;371(17):1650-1. doi: 10.1056/NEJMc1410673. N Engl J Med. 2014. PMID: 25337758 No abstract available.
References
-
- Xia B, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006;22:719–29. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
- U01 CA069417/CA/NCI NIH HHS/United States
- CA128978/CA/NCI NIH HHS/United States
- CA083178/CA/NCI NIH HHS/United States
- 11174/CRUK_/Cancer Research UK/United Kingdom
- U01 CA069467/CA/NCI NIH HHS/United States
- R01 CA175716/CA/NCI NIH HHS/United States
- U01 CA116167/CA/NCI NIH HHS/United States
- R01 CA128978/CA/NCI NIH HHS/United States
- CA116167/CA/NCI NIH HHS/United States
- R01 CA116167/CA/NCI NIH HHS/United States
- P50 CA116201/CA/NCI NIH HHS/United States
- R01 CA157744/CA/NCI NIH HHS/United States
- 10118/CRUK_/Cancer Research UK/United Kingdom
- U01 CA69467/CA/NCI NIH HHS/United States
- U01 CA069638/CA/NCI NIH HHS/United States
- CA116201/CA/NCI NIH HHS/United States
- RC4 CA153828/CA/NCI NIH HHS/United States
- U01 CA69417/CA/NCI NIH HHS/United States
- 15106/CRUK_/Cancer Research UK/United Kingdom
- UM1 CA164920/CA/NCI NIH HHS/United States
- R01 CA097397/CA/NCI NIH HHS/United States
- 11022/CRUK_/Cancer Research UK/United Kingdom
- C12292/A11174/CRUK_/Cancer Research UK/United Kingdom
- U01 CA069398/CA/NCI NIH HHS/United States
- U01 CA069631/CA/NCI NIH HHS/United States
- U01 CA69398/CA/NCI NIH HHS/United States
- CA114236/CA/NCI NIH HHS/United States
- RC4A153828/RC/CCR NIH HHS/United States
- U01 CA083178/CA/NCI NIH HHS/United States
- R35 CA197458/CA/NCI NIH HHS/United States
- 16563/CRUK_/Cancer Research UK/United Kingdom
- U01 CA69638/CA/NCI NIH HHS/United States
- CA097397/CA/NCI NIH HHS/United States
- P30 CA016520/CA/NCI NIH HHS/United States
- R01 CA129639/CA/NCI NIH HHS/United States
- R01CA175716/CA/NCI NIH HHS/United States
- R01 CA114236/CA/NCI NIH HHS/United States
- U01 CA69446/CA/NCI NIH HHS/United States
- U01 CA69631/CA/NCI NIH HHS/United States
- U01 CA069446/CA/NCI NIH HHS/United States
- CA129639/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous